If you believe that the latest blockbuster medication is worth a premium price over your generic brand, or that doctors have access to all the information they need about a drug’s safety and effectiveness each time they write a prescription, Dr. Jerry Avorn has some sobering news. Drawing on more than twenty-five years of patient care, teaching, and research at Harvard Medical School, he shares his firsthand experience of the wide gap in our knowledge of the effectiveness of one medication as compared to another. In Powerful Medicines, he reminds us that every pill we take represents a delicate compromise between the promise of healing, the risk of side effects, and an increasingly daunting price. The stakes on each front grow higher every year as new drugs with impressive power, worrisome side effects, and troubling costs are introduced.
This is a comprehensive behind-the-scenes look at issues that affect everyone: our shortage of data comparing the worth of similar drugs for the same condition; alarming lapses in the detection of lethal side effects; the underuse of life-saving medications; lavish marketing campaigns that influence what doctors prescribe; and the resulting upward spiral of costs that places vital drugs beyond the reach of many Americans.
In this engagingly written book, Dr. Avorn asks questions that will interest every consumer: How can a product judged safe by the Food and Drug Administration turn out to have unexpectedly lethal side effects? Why has the nation’s drug bill been growing at nearly 20 percent per year? How can physicians and patients pick the best medication in its class? How do doctors actually make their prescribing decisions, and why do those decisions sometimes go wrong? Why do so many Americans suffer preventable illnesses and deaths that proper drug use could have averted? How can the nation gain control over its escalating drug budget without resorting to rationing or draconian governmental controls?
Using clinical case histories taken from his own work as a practitioner, researcher, and advocate, Dr. Avorn demonstrates the impressive power of the well-conceived prescription as well as the debacles that can result when medications are misused. He describes an innovative program that employs the pharmaceutical industry’s own marketing techniques to reduce use of some of the most overprescribed and overpriced products. Powerful Medicines offers timely and practical advice on how the nation can improve its drug-approval process, and how patients can work with doctors to make sure their prescriptions are safe, effective, and as affordable as possible.
This is a passionate and provocative call for action as well as a compelling work of clear-headed science.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Jerry Avorn, M.D., is an associate professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital in Boston. An internist, geriatrician, and drug researcher, he is the author of more than two hundred papers in the medical literature on medication use and its outcomes, and one of the most frequently cited researchers in the fields of social science and medicine.
1: THE PREGNANT MARE'S LESSON
In a former British colony, most healers believed the conventional wisdom that a distillation of fluids extracted from the urine of horses, if dried to a powder and fed to aging women, could act as a general tonic, preserve youth, and ward off a variety of diseases. The preparation became enormously popular throughout the culture, and was used widely by older women in all strata of society. Many years later modern scientific studies revealed that long-term ingestion of the horse-urine extract was useless for most of its intended purposes, and that it caused tumors, blood clots, heart disease, and perhaps brain damage.
The former colony is the United States; the time is now; the drug is the family of hormone replacement products that include Prempro and Premarin (manufactured from pregnant mares' urine, hence its name). For decades, estrogen replacement in postmenopausal women was widely believed to have "cardio-protective" properties; other papers in respected medical journals reported that the drugs could treat depression and incontinence, as well as prevent Alzheimer's disease. The first large, well-conducted, controlled clinical trial of this treatment in women was not published until 1998; it found that estrogen replacement actually increased the rate of heart attacks in the patients studied. Another clinical trial published in 2002 presented further evidence that these products increased the risk of heart disease, stroke, and cancer. Further reports a year later found that rather than preventing Alzheimer's disease, the drugs appeared to double the risk of becoming senile. The studies resulted in a reduction, but not an end, to the long-term use of these products.
For decades, these were among the most widely prescribed drugs in the nation. How did we get such an important question so wrong for so long?
Despite the deer-in-the-headlights astonishment with which the nation greeted the 2002 report that hormone replacement caused more harm than good, signs of trouble had been emerging for several years. The estrogen debacle was a case study waiting to happen, and its story can tell us much, both good and bad, about how the health care system evaluates and deploys medications. The fabric of modern medical care is woven of the belief by doctors and patients that the prescription drugs we use have been exhaustively studied and shown to work. The spectacular downfall of estrogen replacement therapy drew attention to the question of just how we determine that a drug actually "works," and why the system broke down in this very high profile case. For years, I've studied how we know what we know about drug benefits and risks, an inquiry I think of as "pharmaco-epistemology." The hormone replacement story is a perfect case study in this domain; it has much to teach us about how fragile our knowledge base can be concerning a drug's ultimate effects.
The word "estrogen" itself comes from the Latin oestrus and the Greek oistros, which mean "gadfly" and, by extension, "frenzy." The roots were chosen by early physiologists to depict the sexual arousal the hormones can cause in animals. They are also related to the semantic lineage of the word "ire," which derives from the Old English words for "haste" and "zeal" as well as from the Greek heiros, or "holy." What better linguistic pedigree for a once-sacred clinical concept that was promoted in haste and defended with zeal, and whose demise precipitated both frenzy and anger? Most important for the present context, the estrogen story has become a gadfly that is provoking a reconsideration of just how we know what we know about a drug’s effectiveness.
The shared delusion about long-term hormone replacement therapy started innocently enough. For centuries, women of a certain age (and their spouses) knew that the end of regular menstruation was often accompanied by the onset of uncomfortable hot flashes, insomnia, and a drying of the internal surface of the vagina. As the new science of physiology developed in the 1900s, these changes were understood to result from a falloff in estrogen production by aging ovaries. If a reduction in natural estrogen was the cause of these problems, then maybe restoring a woman's estrogen to premenopausal levels might ameliorate them. By mid-century it was possible to create a pharmaceutical product that would enable women to replenish their own flagging hormone by ingesting it in pill form. Pregnancy sharply increases the production of estrogens, and they are copiously secreted in the urine. Someone figured out that horses could be used as mass-production hormone factories for this purpose, and pregnant mare’s urine provided Premarin with both its ingredients and its brand name.
By the 1970s, with the support of Ayerst (now Wyeth), the manufacturer of Premarin, Madison Avenue magic redefined the normal age-related reduction in estrogen levels into a new syndrome, "ovarian failure." This novel disease concept was featured prominently in medical journal advertisements for Premarin, which was presented as its logical treatment. And so a normal age-related change took its place alongside kidney failure, congestive heart failure, and liver failure as a newly discovered illness in need of treatment. (I don't intend to belittle the discomfort associated with the hot flashes, vaginal dryness, and other symptoms that accompany menopause, or to suggest that they should not be treated for short periods simply because they are normal. What is at issue is lifelong "replacement therapy.")
Things began to go astray when the temporary management of menopausal symptoms became transformed into a belief that ovarian failure was itself a treatable risk factor for other dread conditions, just as elevated cholesterol or blood pressure was. If that were true, then lifelong drug management would be necessary to tame this risk and prevent a host of horrible clinical outcomes. The concept was fed by public fascination with the idea of a pharmacological fountain of youth for women. The Dupont company had already introduced the motto "Better Living Through Chemistry" to promote its line of household products; a few years later my own generation would co-opt that phrase more ironically in defense of psychedelics. In the same spirit, the 1966 best seller Feminine Forever popularized the notion that a woman's aging (and quite explicitly, her loss of sexual appeal) was now preventable, thanks to pharmaceutical research. Its author, Dr. Robert Wilson, was a gynecologist who took on the curing of menopause as a personal crusade, to save the millions of women who "suffered sweeping metabolic disturbances that literally put them in mortal danger." His views were a twisted precursor of the argument that anatomy isn't destiny; but he seemed to warn that without proper medical attention, physiology could become tragedy:
Though the physical suffering from menopausal effects can be truly dreadful, what impressed me most tragically is the destruction of personality. Some women, when they realize that they are no longer women, subside into a stupor of indifference.... I rest my case on the simple contention that castration is a bad thing and that every woman has the right--indeed, the duty--to counteract the chemical castration that befalls her during her middle years.
A new magic bullet could replace, molecule for molecule, the female hormones that failing ovaries could no longer secrete. Feminine Forever brought this message to women and their doctors all over the country, supplemented by well-placed articles in women's magazines and news releases describing this bold, modern treatment. The company could not legally advertise the drug for long-term use,...
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: World of Books (was SecondSale), Montgomery, IL, USA
Zustand: Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc. Artikel-Nr. 00106870867
Anzahl: 3 verfügbar
Anbieter: ThriftBooks-Atlanta, AUSTELL, GA, USA
Hardcover. Zustand: As New. No Jacket. Pages are clean and are not marred by notes or folds of any kind. ~ ThriftBooks: Read More, Spend Less. Artikel-Nr. G0375414835I2N00
Anzahl: 1 verfügbar
Anbieter: Wonder Book, Frederick, MD, USA
Zustand: Good. Good condition. Good dust jacket. A copy that has been read but remains intact. May contain markings such as bookplates, stamps, limited notes and highlighting, or a few light stains. Artikel-Nr. R08B-02539
Anzahl: 1 verfügbar
Anbieter: BooksRun, Philadelphia, PA, USA
Hardcover. Zustand: Very Good. 1. It's a well-cared-for item that has seen limited use. The item may show minor signs of wear. All the text is legible, with all pages included. It may have slight markings and/or highlighting. Artikel-Nr. 0375414835-11-1
Anzahl: 1 verfügbar
Anbieter: Better World Books: West, Reno, NV, USA
Zustand: Good. Former library copy. Pages intact with minimal writing/highlighting. The binding may be loose and creased. Dust jackets/supplements are not included. Includes library markings. Stock photo provided. Product includes identifying sticker. Better World Books: Buy Books. Do Good. Artikel-Nr. GRP89604176
Anzahl: 1 verfügbar
Anbieter: Better World Books, Mishawaka, IN, USA
Zustand: Very Good. Former library copy. Pages intact with possible writing/highlighting. Binding strong with minor wear. Dust jackets/supplements may not be included. Includes library markings. Stock photo provided. Product includes identifying sticker. Better World Books: Buy Books. Do Good. Artikel-Nr. GRP102667815
Anzahl: 2 verfügbar
Anbieter: Round Table Books, LLC, Gurnee, IL, USA
Hard Cover. Zustand: As New. Zustand des Schutzumschlags: As New. First Edition Thus. 1. Fourth Printing (October 2004). Quarter bound in publisher's gray cloth over gray boards, gilt (black) lettering on spine, fore-edge deckle. 8vo. 448, (2) pp. This is a brand new, unopened, unmarked copy. Both the volume and the unclipped dust jacket are in perfect, pristine condition. AS NEW/AS NEW. 8vo - over 7¾" - 9¾" tall. Artikel-Nr. 5883
Anzahl: 1 verfügbar
Anbieter: Phatpocket Limited, Waltham Abbey, HERTS, Vereinigtes Königreich
Zustand: Good. Your purchase helps support Sri Lankan Children's Charity 'The Rainbow Centre'. Ex-library, so some stamps and wear, but in good overall condition. Our donations to The Rainbow Centre have helped provide an education and a safe haven to hundreds of children who live in appalling conditions. Artikel-Nr. Z1-B-036-01992
Anzahl: 1 verfügbar
Anbieter: Anybook.com, Lincoln, Vereinigtes Königreich
Zustand: Good. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. In good all round condition. Dust jacket in good condition. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,950grams, ISBN:9780375414831. Artikel-Nr. 5956610
Anzahl: 1 verfügbar
Anbieter: Round Table Books, LLC, Gurnee, IL, USA
Hardcover. Zustand: New. Zustand des Schutzumschlags: New. Stated First Edition. First Printing. Quarter bound in publisher's gray cloth over light gray boards, black lettering on spine. . Both the volume and the unclipped ($27.50) dust jacket are in perfect, pristine condition; unread, unmarked, tight, square, and clean. NEW/NEW. Large 8vo 9" - 10" tall. viii, 448, (4) pp. Artikel-Nr. 30290
Anzahl: 1 verfügbar